secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2022-05-19T23:59:59+00:00
Accession:  0001193125-22-155023
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir stockholders elect Sinha and Brenner as Class II directors; ratify Deloitte
--------------------------------------------------------------------------------

- Vikas Sinha elected with 47,229,880 for, 4,036,755 withhold, 10,745,678 broker non-votes.
- Malcolm Brenner elected with 48,449,496 for, 2,817,139 withhold, 10,745,678 broker non-votes.
- Ratification of Deloitte & Touche as auditor approved: 61,754,011 for, 250,317 against, 7,985 abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312522155023/0001193125-22-155023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312522155023/d346922d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-155023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer